Bank of New York Mellon Corp Invests $594,000 in Aquestive Therapeutics, Inc. (NASDAQ:AQST)

Bank of New York Mellon Corp acquired a new stake in shares of Aquestive Therapeutics, Inc. (NASDAQ:AQST) during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm acquired 228,351 shares of the company’s stock, valued at approximately $594,000. Bank of New York Mellon Corp owned 0.25% of Aquestive Therapeutics at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. SG Americas Securities LLC purchased a new position in Aquestive Therapeutics in the 1st quarter worth about $54,000. Lazard Asset Management LLC increased its position in Aquestive Therapeutics by 115.5% during the first quarter. Lazard Asset Management LLC now owns 29,112 shares of the company’s stock worth $124,000 after buying an additional 15,601 shares during the last quarter. Jump Financial LLC bought a new stake in shares of Aquestive Therapeutics during the 4th quarter worth about $60,000. Virtu Financial LLC raised its stake in shares of Aquestive Therapeutics by 219.7% in the 1st quarter. Virtu Financial LLC now owns 102,836 shares of the company’s stock valued at $438,000 after acquiring an additional 70,666 shares in the last quarter. Finally, Janney Montgomery Scott LLC acquired a new position in Aquestive Therapeutics during the first quarter valued at approximately $1,456,000. Institutional investors own 32.45% of the company’s stock.

Wall Street Analysts Forecast Growth

AQST has been the topic of several recent analyst reports. JMP Securities reiterated a “market outperform” rating and issued a $9.00 target price on shares of Aquestive Therapeutics in a report on Monday, August 12th. HC Wainwright reaffirmed a “buy” rating and issued a $9.00 price target on shares of Aquestive Therapeutics in a research report on Wednesday, August 14th. Six analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Buy” and an average target price of $7.83.

Aquestive Therapeutics Trading Down 4.1 %

AQST opened at $4.88 on Tuesday. The firm’s fifty day simple moving average is $4.07 and its 200 day simple moving average is $3.69. Aquestive Therapeutics, Inc. has a 12 month low of $1.25 and a 12 month high of $6.23. The stock has a market capitalization of $444.27 million, a P/E ratio of -11.62 and a beta of 2.84.

Aquestive Therapeutics (NASDAQ:AQST) last announced its quarterly earnings results on Tuesday, August 6th. The company reported ($0.03) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.11) by $0.08. The business had revenue of $20.10 million for the quarter, compared to analyst estimates of $12.62 million. During the same period last year, the firm earned ($0.10) EPS. On average, equities research analysts predict that Aquestive Therapeutics, Inc. will post -0.47 EPS for the current fiscal year.

About Aquestive Therapeutics

Aquestive Therapeutics, Inc operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.